The EMBARK Study
involves 20 study visits over the course of up to 1 year and 3 months (66 weeks).
Approximately 80 participants will be enrolled globally, and they may be reimbursed for travel and expenses.
The investigational drug being studied in patients with atopic dermatitis is under clinical development and is not approved for use by regulatory health authorities. Safety and effectiveness are under evaluation.